Antigen Information

General Information of This Antigen
Antigen ID
TAR0VKDND
Antigen Name
Vascular endothelial growth factor A (VEGFA)
Gene Name
VEGFA
Synonym
VEGF; Vascular permeability factor
Sequence
MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVD
IFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEM
SFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPG
PHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR

    Click to Show/Hide
Family
Paired homeobox family
Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development. Also binds the DEAR/FBXW7-AS1 receptor.

    Click to Show/Hide
Uniprot Entry
VEGFA_HUMAN
HGNC ID
HGNC:12680
KEGG ID
hsa:7422
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
Bevacizumab
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
AB-160
Paclitaxel
Undisclosed
Undisclosed
 ADC Info 
Bevacizumab vedotin
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [1]
 ADC Info 
Bevacizumab-Compound 9
Mertansine DM1
Microtubule (MT)
Bevacizumab-Compound 9 linker
 [2]
 ADC Info 
Bevacizumab-Compound 17
Mertansine DM4
Microtubule (MT)
Bevacizumab-Compound 17 linker
 [2]
 ADC Info 
Bevacizumab-Compound 25
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 25 linker
 [2]
 ADC Info 
Bevacizumab-Compound 31
Auristatin 0101
Microtubule (MT)
Bevacizumab-Compound 31 linker
 [2]
 ADC Info 
Bevacizumab-Compound 36
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 36 linker
 [2]
 ADC Info 
Bevacizumab-Compound 43
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Bevacizumab-Compound 43 linker
 [2]
 ADC Info 
Bevacizumab-Compound 49
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Bevacizumab-Compound 49 linker
 [2]
 ADC Info 
Bevacizumab-Compound 55
Mertansine DM1
Microtubule (MT)
Bevacizumab-Compound 55 linker
 [2]
 ADC Info 
Bevacizumab-Compound 59
Mertansine DM4
Microtubule (MT)
Bevacizumab-Compound 59 linker
 [2]
 ADC Info 
Bevacizumab-Compound 64
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 64 linker
 [2]
 ADC Info 
Bevacizumab-Compound 69
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 69 linker
 [2]
 ADC Info 
Bevacizumab-Compound 74
PBD dimer
Human Deoxyribonucleic acid (hDNA)
Bevacizumab-Compound 74 linker
 [2]
 ADC Info 
Bevacizumab-Compound 75
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 75 linker
 [2]
 ADC Info 
Bevacizumab-Compound 76
Monomethyl auristatin E
Microtubule (MT)
Bevacizumab-Compound 76 linker
 [2]
 ADC Info 
Bevacizumab-Compound 77
Mertansine DM1
Microtubule (MT)
Bevacizumab-Compound 77 linker
 [2]
 ADC Info 
Bevacizumab-Compound 78
Auristatin 0101
Microtubule (MT)
Bevacizumab-Compound 78 linker
 [2]
 ADC Info 
Bevacizumab-Compound 79
Auristatin 0101
Microtubule (MT)
Bevacizumab-Compound 79 linker
 [2]
 ADC Info 
Bevacizumab-Compound 80
Mertansine DM4
Microtubule (MT)
Bevacizumab-Compound 80 linker
 [2]
 ADC Info 
36924655 ADC 32
Monomethyl auristatin E
Undisclosed
Undisclosed
 [3]
 ADC Info 
Bevacizumab-DOX-PDT-1
Doxorubicin; PDT
Undisclosed
Undisclosed
 [4]
 ADC Info 
Bevacizumab-DOX-PDT-2
Doxorubicin; PDT
Undisclosed
Undisclosed
 [4]
 ADC Info 
Bevacizumab fluoresceine 13
Fluoresceine 13
Undisclosed
Undisclosed
 [5]
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
WO2024140927A1-ADC-F (DAR2)
Active metabolite of irinotecan SN38
Undisclosed
CL2A
 [6]
 ADC Info 
WO2024140927A1-ADC-G (DAR2)
Doxorubicin
Undisclosed
Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
 [6]
Undisclosed
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
KSI-601
Undisclosed
Undisclosed
Undisclosed
 [7]
 ADC Info 
CBT-005
Undisclosed
Undisclosed
Undisclosed
 [8]
References
Ref 1 Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023 Aug;137:106575. doi: 10.1016/j.bioorg.2023.106575. Epub 2023 Apr 26.
Ref 2 Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 3 Phenyldivinylsulfonamides for the construction of antibody-drug conjugates with controlled four payloads
Ref 4 Discovery of a Novel ADC for Multifunctional Theranostics: From Vascular Normalization to Synergistic Therapy
Ref 5 Exploring the Chemical Properties and Medicinal Applications of Tetramethylthiocycloheptyne Sulfoximine Used in Strain-Promoted Azide-Alkyne Cycloaddition Reactions
Ref 6 Use of hydroxypropyl-β-cyclodextrin in stabilizing antibody-drug conjugate formulations
Ref 7 Kodiak biopharmaceutical company product pipeline
Ref 8 Cloudbreak pharmaceutical company product pipeline